Liminatus Pharma, Inc.
No SEC Form 4 filings for $LIMN in the last 30 days.
Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001971387 0001971387 2026-08-03 2026-08-03 0001971387 us-gaap:CommonClassAMember 2026-08-03 2026-08-03 0001971387 us-gaap:WarrantMember 2026-08-03 2026-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha
Liminatus Pharma (NASDAQ:LIMN) shares rose 30.49% to $0.15 in after-hours after the company amended and restated its merger agreement with InnocsAI LLC. The revised terms aim to let the deal close before shareholder approval, expected Thursday, with consideration valued at $0.20 per share plus contingent value rights.
Over the past 7 days, alphai's AI scored 1 news story mentioning LIMN (Liminatus Pharma, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent LIMN coverage spans financial news, mergers & acquisitions and corporate actions.
The approved reverse split authorization is a capital-markets and liquidity catalyst that can affect near-term trading dynamics and dilution optics.
Closing of the merger/subsidiary acquisition is a balance-sheet and risk-profile change for LIMN, with consideration paid in LIMN common stock plus contingent value rights.
Amended merger terms (shareholder-approval bypass, new consideration mix, and Thursday closing expectation) are a direct catalyst for LIMN’s near-term risk/reward.
Deal structure change (mix of common + non-voting convertible preferred) and earlier closing window can re-rate deal certainty and dilution expectations.
Liminatus Pharma's recent public offering indicates a strategic move to raise capital for growth and development. The issuance of shares and warrants at a modest price suggests a cautious approach, possibly reflecting current market conditions or company valuation.
alphai scores every news story that mentions LIMN with an AI model for sentiment and relevance, and aggregates insider trades from Liminatus Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001971387 0001971387 2026-08-03 2026-08-03 0001971387 us-gaap:CommonClassAMember 2026-08-03 2026-08-03 0001971387 us-gaap:WarrantMember 2026-08-03 2026-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
2 min readLiminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha
3 min readLiminatus Pharma (NASDAQ:LIMN) shares rose 30.49% to $0.15 in after-hours after the company amended and restated its merger agreement with InnocsAI LLC. The revised terms aim to let the deal close before shareholder approval, expected Thursday, with consideration valued at $0.20 per share plus contingent value rights.
3 min readLiminatus Pharma (LIMN) amended its merger agreement with InnocsAI LLC to expand its oncology pipeline. The deal is now expected to close July 2, 2026, before stockholder approval. InnocsAI holders will receive Liminatus common stock and newly designated non-voting convertible preferred issued at $0.20/share, implying ~$320M value, plus CVRs on 20% of future net proceeds.
4 min readLiminatus Pharma, Inc. (NASDAQ: LIMN), a pre-clinical stage immuno-oncology company, announced the pricing of a public offering expected to raise approximately $4.0 million in gross proceeds. The offering includes 13,813,000 shares (or pre-funded warrants) and warrants to purchase up to 20,719,500 shares, at a combined price of $0.29 per share. The company plans to use the net proceeds for working capital, general corporate purposes, and advancing its business objectives.
2 min readLA PALMA, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Liminatus Pharma, Inc. ( NASDAQ:LIMN ) , a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding ( MOU ) with Capital Trust Group ...
2 min readLA PALMA, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Liminatus Pharma, Inc. ( NASDAQ: LIMN ) , a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding ( MOU ) with Capital Trust Group ...
3 min readSubject to completion of diligence and the negotiation of definitive agreements, CTG intends to subscribe to newly issued shares of Liminatus, subject to compliance with Nasdaq listing rules and U.S. securities laws.
2 min readLiminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to ...
4 min readLA PALMA, Calif., July 25, 2025 ( GLOBE NEWSWIRE ) -- Liminatus Pharma, Inc.
3 min read
